{"id":5761,"date":"2022-08-24T07:28:08","date_gmt":"2022-08-24T05:28:08","guid":{"rendered":"https:\/\/www.msd.ch\/fr\/?page_id=5761"},"modified":"2024-07-16T07:20:22","modified_gmt":"2024-07-16T05:20:22","slug":"lyfnua-publication-of-clinical-trial-results","status":"publish","type":"page","link":"https:\/\/www.msd.ch\/fr\/lyfnua-publication-of-clinical-trial-results\/","title":{"rendered":"Lyfnua &#8211; Publication des r\u00e9sultats d\u2019\u00e9tudes cliniques"},"content":{"rendered":"\n<h1 class=\"wp-block-heading\">Publication des r\u00e9sultats d\u2019\u00e9tudes cliniques<\/h1>\n\n\n\n<p>Les informations ci-dessous ainsi que les liens correspondant aux donn\u00e9es cliniques r\u00e9pondent aux exigences des articles 71 \u00e0 73 de l\u2019Ordonnance sur les m\u00e9dicaments (Ordonnance sur les m\u00e9dicaments, OM\u00e9d) et compl\u00e8tent les informations publi\u00e9es en lien avec l\u2019autorisation suisse des m\u00e9dicaments correspondants.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">LYFNUA\u00ae<\/h2>\n\n\n\n<p>Lyfnua\u00ae (Gefapixant), comprim\u00e9s pellicul\u00e9s, 45 mg<\/p>\n\n\n\n<p>Num\u00e9ro d&#8217;autorisation: 68065<\/p>\n\n\n\n<p>Date de l&#8217;autorisation de mise sur le march\u00e9: 24-Mai-2022<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><br><strong><strong>\u00c9tudes cliniques<\/strong><\/strong><\/h4>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>1.&nbsp; COUGH-1 (Protocol 027)<\/strong><\/h4>\n\n\n\n<p><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03449134?term=gefapixant&amp;draw=3&amp;rank=16\">A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027) \u2013 ClinicalTrials.gov<\/a><br>NCT03449134<\/p>\n\n\n\n<p><strong>Publications<\/strong>:<br>McGarvey LP, Birring SS, Morice AH, Dicpinigaitis PV, Pavord ID, Schelfhout J, Nguyen AM, Li Q, Tzontcheva A, Iskold B, Green SA, Rosa C, Muccino DR, Smith JA; COUGH-1 and COUGH-2 Investigators. Efficacy and safety of gefapixant, a P2X(3) receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet. 2022 Mar 5;399(10328):909-923. doi: 10.1016\/S0140-6736(21)02348-5.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>2. COUGH-2 (Protocol 030)<\/strong><\/h4>\n\n\n\n<p><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03449147?term=gefapixant&amp;draw=3&amp;rank=19\">A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030) \u2013 ClinicalTrials.gov<\/a><br>NCT03449147<\/p>\n\n\n\n<p><strong>Publications<\/strong>:<br>McGarvey LP, Birring SS, Morice AH, Dicpinigaitis PV, Pavord ID, Schelfhout J, Nguyen AM, Li Q, Tzontcheva A, Iskold B, Green SA, Rosa C, Muccino DR, Smith JA; COUGH-1 and COUGH-2 Investigators. Efficacy and safety of gefapixant, a P2X(3) receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet. 2022 Mar 5;399(10328):909-923. doi: 10.1016\/S0140-6736(21)02348-5.<\/p>\n\n\n\n<p><sup>CH-OGM-00002, 07\/2024<\/sup><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Publication des r\u00e9sultats d\u2019\u00e9tudes cliniques Les informations ci-dessous ainsi que les liens correspondant aux donn\u00e9es cliniques r\u00e9pondent aux exigences des articles 71 \u00e0 73 de l\u2019Ordonnance sur les m\u00e9dicaments (Ordonnance sur les m\u00e9dicaments, OM\u00e9d) et compl\u00e8tent les informations publi\u00e9es en lien avec l\u2019autorisation suisse des m\u00e9dicaments correspondants. LYFNUA\u00ae Lyfnua\u00ae (Gefapixant), comprim\u00e9s pellicul\u00e9s, 45 mg Num\u00e9ro [&hellip;]<\/p>\n","protected":false},"author":282,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"editor_notices":[],"footnotes":""},"class_list":["post-5761","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.9.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Lyfnua - Publication des r\u00e9sultats d\u2019\u00e9tudes cliniques - msd.ch<\/title>\n<meta name=\"description\" content=\"Publication des r\u00e9sultats des \u00e9tudes cliniques sur Lyfnua\u00ae (Gefapixant), autoris\u00e9 par Swissmedic le 24 mai 2022.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.msd.ch\/fr\/lyfnua-publication-of-clinical-trial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lyfnua - Publication des r\u00e9sultats d\u2019\u00e9tudes cliniques - msd.ch\" \/>\n<meta property=\"og:description\" content=\"Publication des r\u00e9sultats des \u00e9tudes cliniques sur Lyfnua\u00ae (Gefapixant), autoris\u00e9 par Swissmedic le 24 mai 2022.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.msd.ch\/fr\/lyfnua-publication-of-clinical-trial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"msd.ch\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-16T05:20:22+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.msd.ch\/fr\/lyfnua-publication-of-clinical-trial-results\/\",\"url\":\"https:\/\/www.msd.ch\/fr\/lyfnua-publication-of-clinical-trial-results\/\",\"name\":\"Lyfnua - Publication des r\u00e9sultats d\u2019\u00e9tudes cliniques - msd.ch\",\"isPartOf\":{\"@id\":\"https:\/\/www.msd.ch\/fr\/#website\"},\"datePublished\":\"2022-08-24T05:28:08+00:00\",\"dateModified\":\"2024-07-16T05:20:22+00:00\",\"description\":\"Publication des r\u00e9sultats des \u00e9tudes cliniques sur Lyfnua\u00ae (Gefapixant), autoris\u00e9 par Swissmedic le 24 mai 2022.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.msd.ch\/fr\/lyfnua-publication-of-clinical-trial-results\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.msd.ch\/fr\/#website\",\"url\":\"https:\/\/www.msd.ch\/fr\/\",\"name\":\"msd.ch\",\"description\":\"MSD recherche et d\u00e9veloppe des m\u00e9dicaments et des vaccins pour sauver des vies et am\u00e9liorer la sant\u00e9 des patients. En Suisse, 1000 employ\u00e9s \u00e0 Lucerne et \u00e0 Zurich s&#039;engagent dans ce sens.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.msd.ch\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lyfnua - Publication des r\u00e9sultats d\u2019\u00e9tudes cliniques - msd.ch","description":"Publication des r\u00e9sultats des \u00e9tudes cliniques sur Lyfnua\u00ae (Gefapixant), autoris\u00e9 par Swissmedic le 24 mai 2022.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.msd.ch\/fr\/lyfnua-publication-of-clinical-trial-results\/","og_locale":"en_US","og_type":"article","og_title":"Lyfnua - Publication des r\u00e9sultats d\u2019\u00e9tudes cliniques - msd.ch","og_description":"Publication des r\u00e9sultats des \u00e9tudes cliniques sur Lyfnua\u00ae (Gefapixant), autoris\u00e9 par Swissmedic le 24 mai 2022.","og_url":"https:\/\/www.msd.ch\/fr\/lyfnua-publication-of-clinical-trial-results\/","og_site_name":"msd.ch","article_modified_time":"2024-07-16T05:20:22+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.msd.ch\/fr\/lyfnua-publication-of-clinical-trial-results\/","url":"https:\/\/www.msd.ch\/fr\/lyfnua-publication-of-clinical-trial-results\/","name":"Lyfnua - Publication des r\u00e9sultats d\u2019\u00e9tudes cliniques - msd.ch","isPartOf":{"@id":"https:\/\/www.msd.ch\/fr\/#website"},"datePublished":"2022-08-24T05:28:08+00:00","dateModified":"2024-07-16T05:20:22+00:00","description":"Publication des r\u00e9sultats des \u00e9tudes cliniques sur Lyfnua\u00ae (Gefapixant), autoris\u00e9 par Swissmedic le 24 mai 2022.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.msd.ch\/fr\/lyfnua-publication-of-clinical-trial-results\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.msd.ch\/fr\/#website","url":"https:\/\/www.msd.ch\/fr\/","name":"msd.ch","description":"MSD recherche et d\u00e9veloppe des m\u00e9dicaments et des vaccins pour sauver des vies et am\u00e9liorer la sant\u00e9 des patients. En Suisse, 1000 employ\u00e9s \u00e0 Lucerne et \u00e0 Zurich s&#039;engagent dans ce sens.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.msd.ch\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/pages\/5761","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/users\/282"}],"replies":[{"embeddable":true,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/comments?post=5761"}],"version-history":[{"count":4,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/pages\/5761\/revisions"}],"predecessor-version":[{"id":7693,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/pages\/5761\/revisions\/7693"}],"wp:attachment":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/media?parent=5761"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}